E-viri
Recenzirano
-
Yamamoto, Yoshiaki; Yatsuda, Junji; Shimokawa, Mototsugu; Fuji, Nakanori; Aoki, Akihiko; Sakano, Shigeru; Yamamoto, Mitsutaka; Suga, Akinobu; Tei, Yasuhide; Yoshihiro, Satoru; Kitahara, Seiji; Nagao, Kazuhiro; Takai, Kimio; Kamiryo, Yoriaki; Akao, Jumpei; Yamaguchi, Shiro; Oba, Kazuo; Shimabukuro, Tomoyuki; Matsumoto, Hiroaki; Kamba, Tomomi; Matsuyama, Hideyasu
International journal of clinical oncology, 2021/1, Letnik: 26, Številka: 1Journal Article
Background Pembrolizumab is effective in a limited number of patients with advanced urothelial carcinoma (UC). Therefore, we evaluated the prognostic value of clinical biomarkers following pembrolizumab treatment in patients with advanced UC. Methods We retrospectively reviewed the medical records of 121 patients with platinum-refractory advanced UC who received pembrolizumab. Inflammation-based prognostic scores before and 6 weeks after the treatment were recorded. The categorical variables influencing overall survival (OS) and objective response rate (ORR) were analyzed. Results Multivariate analyses showed that pretreatment Eastern Cooperative Oncology Group (ECOG) performance score (PS), presence of only lymph node metastasis (only LN mets), C-reactive protein (CRP), and neutrophil/lymphocyte ratio (NLR) were independent prognostic factors for OS ( P = 0.0077; RR = 2.42, P = 0.0049; RR = 0.36, P = 0.0047; RR = 2.53, and P = 0.0079; RR = 2.33, respectively). The pretreatment risk stratification using ECOG PS, only LN mets, CRP, and NLR was used for estimating the OS ( P < 0.0001) and ORR ( P < 0.0001). Furthermore, changes in NLR in response to pembrolizumab were significantly associated with the OS ( P = 0.0002) and ORR ( P = 0.0023). This change was also significantly correlated with OS even in the high-risk group stratified by this pretreatment risk stratification ( P = 0.0069). Conclusions This pretreatment risk stratification may be used for estimating the OS and ORR of patients with advanced UC treated with pembrolizumab. If changes in NLR in response to pembrolizumab treatment improve, pembrolizumab should be continued.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.